Drug Price Trends for DALFAMPRIDINE ER

Average Pharmacy Cost for DALFAMPRIDINE ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
DALFAMPRIDINE ER 10 MG TABLET	67877-0444-60	0.51378	EACH	2025-03-19
DALFAMPRIDINE ER 10 MG TABLET	00591-2533-60	0.51378	EACH	2025-03-19
DALFAMPRIDINE ER 10 MG TABLET	16729-0292-12	0.51378	EACH	2025-03-19
DALFAMPRIDINE ER 10 MG TABLET	62756-0429-86	0.51378	EACH	2025-03-19

Market Analysis and Price Projections for Dalfampridine ER

Introduction to Dalfampridine ER

Dalfampridine ER, known by its brand name Ampyra, is a medication that belongs to the class of miscellaneous central nervous system agents. It is primarily used to improve walking speed in patients with multiple sclerosis (MS) and is now being explored for the treatment of episodic ataxia type 2 (EA 2)[1][4][5].

Current Market Status

Usage and Indications

Dalfampridine ER is widely recognized for its efficacy in improving walking speed in patients with MS. Clinical trials have shown that it increases walking speed by an average of approximately 25% from baseline in responding patients[4].

Expansion into New Indications

Solaxa is currently developing Dalfampridine ER for the treatment of episodic ataxia type 2, a condition characterized by intermittent episodes of ataxia. This development is in Phase II, and the drug is administered as an extended-release tablet targeting voltage-gated potassium channels (KCNN)[1].

Market Size and Growth

Global Market Trends

The global dalfampridine market is expected to experience significant growth, driven by the increasing prevalence of MS and the potential expansion into new indications such as EA 2. The 10 mg segment of dalfampridine, which is the most commonly used dosage, accounted for a noticeable share of the global market in 2023 and is projected to continue growing[3].

Regional Analysis

The market for dalfampridine is expected to be dominated by regions with high MS prevalence, such as North America and Europe. These regions have well-established healthcare systems and a higher demand for treatments that improve the quality of life for MS patients[3].

Pricing and Cost Considerations

Current Pricing

The cost of dalfampridine ER varies significantly depending on whether it is purchased as the brand name Ampyra or as a generic version. Ampyra 10 mg oral tablets can cost around $4,492 for a supply of 60 tablets, while the generic version (dalfampridine) costs approximately $137 for the same quantity[2][5].

Patient Assistance Programs

To make the medication more accessible, patient assistance programs (PAPs) and copay cards are available. For example, eligible commercially insured patients may pay as little as $10 per monthly prescription of Ampyra, with annual maximum savings of $12,000[5].

Price Projections

Short-Term Projections

In the short term, the price of dalfampridine ER is likely to remain stable, with potential minor fluctuations due to market competition and the availability of generic versions. The introduction of generic dalfampridine has already led to a significant reduction in costs for patients, making the medication more affordable[2][5].

Long-Term Projections

Long-term price projections suggest that the cost of dalfampridine ER could decrease further as more generic versions enter the market. Additionally, the expansion into new indications such as EA 2 may lead to increased demand, which could stabilize or slightly increase prices due to higher production volumes and market demand[1][3].

Market Drivers and Restraints

Drivers

• Increasing Prevalence of MS: The growing number of MS cases globally is a significant driver for the dalfampridine market.
• Expansion into New Indications: The potential approval for EA 2 treatment could expand the market size.
• Generic Competition: The availability of generic versions reduces costs and increases accessibility, driving market growth[1][3][5].

Restraints

• High Development Costs: The cost of developing and bringing new indications to market can be a significant restraint.
• Regulatory Hurdles: The approval process for new indications can be lengthy and uncertain, affecting market growth.
• Side Effects and Safety Concerns: Dalfampridine ER has associated side effects and safety concerns, such as the risk of seizures, which can impact market adoption[1][4].

Competitive Landscape

The competitive landscape for dalfampridine ER includes both brand and generic manufacturers. The brand name Ampyra, while expensive, offers a well-established reputation and patient assistance programs. Generic versions, on the other hand, provide a more affordable alternative, increasing competition and driving down prices[2][5].

Conclusion

Dalfampridine ER is a significant player in the market for central nervous system agents, particularly for MS treatment. As it expands into new indications like EA 2, the market is expected to grow. However, pricing will be influenced by the balance between brand and generic competition, patient assistance programs, and regulatory approvals.

Key Takeaways

• Market Growth: The dalfampridine market is expected to grow driven by increasing MS prevalence and expansion into new indications.
• Pricing: The cost of dalfampridine ER varies widely between brand and generic versions, with patient assistance programs available to reduce costs.
• Competitive Landscape: The market is competitive with both brand and generic manufacturers, influencing pricing and market dynamics.
• Regulatory Factors: Approval for new indications and regulatory hurdles can significantly impact market growth and pricing.

FAQs

What is the primary use of Dalfampridine ER?

Dalfampridine ER is primarily used to improve walking speed in patients with multiple sclerosis (MS).

Is Dalfampridine ER being developed for other conditions?

Yes, it is currently in Phase II clinical trials for the treatment of episodic ataxia type 2 (EA 2).

How much does Dalfampridine ER cost?

The cost varies significantly; the brand name Ampyra can cost around $4,492 for 60 tablets, while the generic version costs approximately $137 for the same quantity.

Are there patient assistance programs available for Dalfampridine ER?

Yes, patient assistance programs and copay cards are available to make the medication more affordable.

What are the potential side effects of Dalfampridine ER?

Dalfampridine ER has associated side effects, including the risk of seizures, and other safety concerns that need to be monitored.

Sources

1. Pharmaceutical Technology: "Dalfampridine ER by Solaxa for Episodic Ataxia Type 2"
2. Drugs.com: "Dalfampridine Prices, Coupons, Copay Cards & Patient Assistance"
3. Cognitive Market Research: "Dalfampridine Market Report 2024 (Global Edition)"
4. Ampyra-HCP: "Clinical Study Results - AMPYRA® (dalfampridine)"
5. Drugs.com: "Ampyra Prices, Coupons, Copay Cards & Patient Assistance"